• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

Susceptibility Gene for Asthma Identified

Article

Researchers have identified a gene conferring susceptibility to asthma in populations of European descent, according to research published online April 9 in the New England Journal of Medicine.

WEDNESDAY, April 9 (HealthDay News) -- Researchers have identified a gene conferring susceptibility to asthma in populations of European descent, according to research published online April 9 in the New England Journal of Medicine.

Carole Ober, Ph.D., of the University of Chicago, and colleagues performed a genome-wide association study to identify genes affecting serum levels of the chitinase-like protein, YKL-40, in 753 Hutterites, a founder population of European descent. The researchers then investigated the association of an implicated single-nucleotide polymorphism (SNP) with asthma in the Hutterites, in two unrelated case-control populations of European descent and in a birth-cohort of children of European descent at high-risk for asthma.

A promoter SNP upstream from the gene encoding YKL-40, the chitinase 3-like 1 (CHI3L1) gene, was associated with serum YKL-40 levels, asthma, bronchial hyperresponsiveness and pulmonary function measures in the Hutterite population. In addition, this SNP predicted the presence of asthma in the two case-control populations and serum YKL-40 levels in the birth cohort.

These findings suggest that "CHI3L1 is a susceptibility gene for asthma, bronchial hyperresponsiveness and reduced lung function, and elevated YKL-40 levels are a biomarker for asthma and decline in lung function," the authors conclude.

Two study authors disclosed receiving consulting fees and grant support from pharmaceutical companies, including MedImmune, a company investigating YKL-40 as a potential therapeutic target in asthma. One co-author is an inventor for a chitinase assay licensed to MedImmune.

AbstractFull TextEditorial

Copyright © 2008 ScoutNews, LLC. All rights reserved.

Related Videos
Natasha Hoyte, MPH, CPNP-PC
Lauren Flagg
Venous thromboembolism, Heparin-induced thrombocytopenia, and direct oral anticoagulants | Image credit: Contemporary Pediatrics
Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
Sally Humphrey, DNP, APRN, CPNP-PC | Image Credit: Contemporary Pediatrics
Ashley Gyura, DNP, CPNP-PC | Image Credit: Children's Minnesota
Congenital heart disease and associated genetic red flags
Traci Gonzales, MSN, APRN, CPNP-PC
© 2024 MJH Life Sciences

All rights reserved.